Company profile MRUS
After 39 days of this quarter the interest is at 30.0. Based on that we can calculate that during remaining 52 days it will total up to 70.0. antibody therapeutics expected interest is significantly lower compared to previous quarter (-46.2%) and same quarter last year (-41.7%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 48 | 55 14.6% QoQ | 74 34.5% QoQ | 39 -47.3% QoQ |
| 2020 | 86 79.2% YoY 120.5% QoQ | 272 394.5% YoY 216.3% QoQ | 107 44.6% YoY -60.7% QoQ | 89 128.2% YoY -16.8% QoQ |
| 2021 | 102 18.6% YoY 14.6% QoQ | 32 -88.2% YoY -68.6% QoQ | 93 -13.1% YoY 190.6% QoQ | 68 -23.6% YoY -26.9% QoQ |
| 2022 | 129 26.5% YoY 89.7% QoQ | 106 231.2% YoY -17.8% QoQ | 102 9.7% YoY -3.8% QoQ | 102 50.0% YoY 0.0% QoQ |
| 2023 | 120 -7.0% YoY 17.6% QoQ | 105 -0.9% YoY -12.5% QoQ | 128 25.5% YoY 21.9% QoQ | 130 27.5% YoY 1.6% QoQ |
| 2024 | 30 -75.0% YoY -76.9% QoQ | - | - | - |
The average 5 years interest of antibody therapeutics was 7.73 per week. The last year interest of antibody therapeutics compared to the last 5 years has changed by 14.23%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 89.08%.
There is not enough data for Zenocutuzumab (MCLA-128) -phase 2 clinical trials to provide analysis
There is not enough data for Zenocutuzumab (MCLA-128) -phase 2 clinical trials to provide correlation calculation
There is not enough data for Zenocutuzumab (MCLA-128) -phase 2 clinical trials to provide analysis
After 39 days of this quarter the interest is at 200.0. Based on that we can calculate that during remaining 52 days it will total up to 467.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 358 | 638 78.2% QoQ | 595 -6.7% QoQ | 666 11.9% QoQ |
| 2020 | 660 84.4% YoY -0.9% QoQ | 529 -17.1% YoY -19.8% QoQ | 692 16.3% YoY 30.8% QoQ | 705 5.9% YoY 1.9% QoQ |
| 2021 | 686 3.9% YoY -2.7% QoQ | 670 26.7% YoY -2.3% QoQ | 692 0.0% YoY 3.3% QoQ | 707 0.3% YoY 2.2% QoQ |
| 2022 | 677 -1.3% YoY -4.2% QoQ | 653 -2.5% YoY -3.5% QoQ | 720 4.0% YoY 10.3% QoQ | 876 23.9% YoY 21.7% QoQ |
| 2023 | 699 3.2% YoY -20.2% QoQ | 602 -7.8% YoY -13.9% QoQ | 574 -20.3% YoY -4.7% QoQ | 585 -33.2% YoY 1.9% QoQ |
| 2024 | 200 -71.4% YoY -65.8% QoQ | - | - | - |
The average 5 years interest of metastatic breast cancer was 50.51 per week. The last year interest of metastatic breast cancer compared to the last 5 years has changed by -11.9%. The interest for metastatic breast cancer is seasonal. The last year interest is comparable to 5 years ago. It has changed only by -8.49%.
After 39 days of this quarter the interest is at 149.0. Based on that we can calculate that during remaining 52 days it will total up to 348.0. castration-resistant prostate cancer expected interest is significantly higher compared to same quarter last year (+73.1%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 202 | 331 63.9% QoQ | 204 -38.4% QoQ | 295 44.6% QoQ |
| 2020 | 218 7.9% YoY -26.1% QoQ | 325 -1.8% YoY 49.1% QoQ | 118 -42.2% YoY -63.7% QoQ | 276 -6.4% YoY 133.9% QoQ |
| 2021 | 397 82.1% YoY 43.8% QoQ | 265 -18.5% YoY -33.2% QoQ | 174 47.5% YoY -34.3% QoQ | 180 -34.8% YoY 3.4% QoQ |
| 2022 | 221 -44.3% YoY 22.8% QoQ | 213 -19.6% YoY -3.6% QoQ | 330 89.7% YoY 54.9% QoQ | 310 72.2% YoY -6.1% QoQ |
| 2023 | 201 -9.0% YoY -35.2% QoQ | 347 62.9% YoY 72.6% QoQ | 328 -0.6% YoY -5.5% QoQ | 290 -6.5% YoY -11.6% QoQ |
| 2024 | 149 -25.9% YoY -48.6% QoQ | - | - | - |
The average 5 years interest of castration-resistant prostate cancer was 20.59 per week. The last year interest of castration-resistant prostate cancer compared to the last 5 years has changed by 14.42%. The interest for castration-resistant prostate cancer is seasonal. The last year interest is comparable to 5 years ago. It has changed only by 13.32%.
After 39 days of this quarter the interest is at 267.0. Based on that we can calculate that during remaining 52 days it will total up to 623.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 306 | 412 34.6% QoQ | 434 5.3% QoQ | 380 -12.4% QoQ |
| 2020 | 401 31.0% YoY 5.5% QoQ | 417 1.2% YoY 4.0% QoQ | 435 0.2% YoY 4.3% QoQ | 471 23.9% YoY 8.3% QoQ |
| 2021 | 435 8.5% YoY -7.6% QoQ | 384 -7.9% YoY -11.7% QoQ | 402 -7.6% YoY 4.7% QoQ | 440 -6.6% YoY 9.5% QoQ |
| 2022 | 643 47.8% YoY 46.1% QoQ | 619 61.2% YoY -3.7% QoQ | 517 28.6% YoY -16.5% QoQ | 494 12.3% YoY -4.4% QoQ |
| 2023 | 724 12.6% YoY 46.6% QoQ | 643 3.9% YoY -11.2% QoQ | 597 15.5% YoY -7.2% QoQ | 585 18.4% YoY -2.0% QoQ |
| 2024 | 267 -63.1% YoY -54.4% QoQ | - | - | - |
The average 5 years interest of solid tumors was 38.34 per week. The last year interest of solid tumors compared to the last 5 years has changed by 25.04%. The interest for solid tumors is trending. The last year interest is quite higher compared to 5 years ago. It has increased by 46.02%.
After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0. Neuregulin 1 expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 22 | 55 150.0% QoQ | 25 -54.5% QoQ | 127 408.0% QoQ |
| 2020 | 39 77.3% YoY -69.3% QoQ | 129 134.5% YoY 230.8% QoQ | 61 144.0% YoY -52.7% QoQ | 71 -44.1% YoY 16.4% QoQ |
| 2021 | 93 138.5% YoY 31.0% QoQ | 69 -46.5% YoY -25.8% QoQ | 41 -32.8% YoY -40.6% QoQ | 24 -66.2% YoY -41.5% QoQ |
| 2022 | 123 32.3% YoY 412.5% QoQ | 18 -73.9% YoY -85.4% QoQ | 54 31.7% YoY 200.0% QoQ | 54 125.0% YoY 0.0% QoQ |
| 2023 | 113 -8.1% YoY 109.3% QoQ | 38 111.1% YoY -66.4% QoQ | 181 235.2% YoY 376.3% QoQ | 47 -13.0% YoY -74.0% QoQ |
| 2024 | 0 -100.0% YoY -100.0% QoQ | - | - | - |
The average 5 years interest of Neuregulin 1 was 5.3 per week. The last year interest of Neuregulin 1 compared to the last 5 years has changed by 7.74%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 19.71%.
There is not enough data for MCLA-158 -phase 1 clinical trial to provide analysis
There is not enough data for MCLA-158 -phase 1 clinical trial to provide correlation calculation
There is not enough data for MCLA-158 -phase 1 clinical trial to provide analysis
There is not enough data for MCLA-145 -phase 1 clinical trials to provide analysis
There is not enough data for MCLA-145 -phase 1 clinical trials to provide correlation calculation
There is not enough data for MCLA-145 -phase 1 clinical trials to provide analysis
There is not enough data for MCLA-129 -phase 1/2 clinical trials to provide analysis
There is not enough data for MCLA-129 -phase 1/2 clinical trials to provide correlation calculation
There is not enough data for MCLA-129 -phase 1/2 clinical trials to provide analysis
After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0. advanced non-small cell lung cancer expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 128 | 178 39.1% QoQ | 106 -40.4% QoQ | 135 27.4% QoQ |
| 2020 | 118 -7.8% YoY -12.6% QoQ | 58 -67.4% YoY -50.8% QoQ | 55 -48.1% YoY -5.2% QoQ | 91 -32.6% YoY 65.5% QoQ |
| 2021 | 128 8.5% YoY 40.7% QoQ | 61 5.2% YoY -52.3% QoQ | 150 172.7% YoY 145.9% QoQ | 155 70.3% YoY 3.3% QoQ |
| 2022 | 87 -32.0% YoY -43.9% QoQ | 102 67.2% YoY 17.2% QoQ | 157 4.7% YoY 53.9% QoQ | 90 -41.9% YoY -42.7% QoQ |
| 2023 | 218 150.6% YoY 142.2% QoQ | 182 78.4% YoY -16.5% QoQ | 47 -70.1% YoY -74.2% QoQ | 47 -47.8% YoY 0.0% QoQ |
| 2024 | 0 -100.0% YoY -100.0% QoQ | - | - | - |
The average 5 years interest of advanced non-small cell lung cancer was 8.79 per week. The last year interest of advanced non-small cell lung cancer compared to the last 5 years has changed by -4.21%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -28.1%.
There is not enough data for ONO-4685 -Phase 1 clinical trial to provide analysis
There is not enough data for ONO-4685 -Phase 1 clinical trial to provide correlation calculation
There is not enough data for ONO-4685 -Phase 1 clinical trial to provide analysis
There is not enough data for relapsed/refractory T cell lymphoma to provide analysis
There is not enough data for relapsed/refractory T cell lymphoma to provide correlation calculation
There is not enough data for relapsed/refractory T cell lymphoma to provide analysis
There is not enough data for Betta Pharmaceuticals Ltd to provide analysis
There is not enough data for Betta Pharmaceuticals Ltd to provide correlation calculation
There is not enough data for Betta Pharmaceuticals Ltd to provide analysis
After 39 days of this quarter the interest is at 248.0. Based on that we can calculate that during remaining 52 days it will total up to 579.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 375 | 626 66.9% QoQ | 594 -5.1% QoQ | 628 5.7% QoQ |
| 2020 | 689 83.7% YoY 9.7% QoQ | 729 16.5% YoY 5.8% QoQ | 685 15.3% YoY -6.0% QoQ | 564 -10.2% YoY -17.7% QoQ |
| 2021 | 727 5.5% YoY 28.9% QoQ | 693 -4.9% YoY -4.7% QoQ | 616 -10.1% YoY -11.1% QoQ | 608 7.8% YoY -1.3% QoQ |
| 2022 | 696 -4.3% YoY 14.5% QoQ | 628 -9.4% YoY -9.8% QoQ | 686 11.4% YoY 9.2% QoQ | 560 -7.9% YoY -18.4% QoQ |
| 2023 | 707 1.6% YoY 26.2% QoQ | 674 7.3% YoY -4.7% QoQ | 678 -1.2% YoY 0.6% QoQ | 664 18.6% YoY -2.1% QoQ |
| 2024 | 248 -64.9% YoY -62.7% QoQ | - | - | - |
The average 5 years interest of Incyte was 50.1 per week. The last year interest of Incyte compared to the last 5 years has changed by 1.88%. The interest for Incyte is seasonal. The last year interest is comparable to 5 years ago. It has changed only by 5.41%.